Penn Phase One Study Shows CD19 And BCMA CAR T Therapy Enables Kidney Transplants For Highly Sensitized Patients

Penn Researchers Use CAR T Therapy To Enable kidney Transplants For Highly Sensitized Patients

USA: A phase one study published June 3, 2026, from the University of Pennsylvania reports that three highly sensitized people received kidney transplants after receiving CAR T therapy. The small trial aimed at a population often excluded from transplantation because their immune systems carry antibodies that reject nearly every available donor kidney.

Researchers at Penn administered CD19- and BCMA-targeted CAR T cells to reduce the immune cells driving rejection, producing a window in which transplantation could proceed. The intervention was designed to lower the cellular forces that make matching so difficult for sensitized patients rather than to change donor-recipient compatibility itself.

All three study participants went on to receive kidney transplants following the CAR T treatment. The investigators stress that this is early-stage work: the approach does not solve the underlying challenge of finding immunologic matches, and longer follow-up and larger trials are needed to assess durability, safety, and broader applicability.

Still, the results point to a potential new pathway for people once considered nearly impossible to treat. If validated, CAR T–based strategies could expand access to kidney transplantation for highly sensitized patients and reshape how transplant teams approach immune barriers to organ acceptance.

Video originally published on 2026-06-06 07:54:35